Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results
Purpose: We performed a phase I clinical trial of adenovirus/prostate-specific antigen (PSA) vaccine in men with measurable metastatic hormone-refractory disease. Experimental Design: Men with measurable metastatic disease received one vaccine injection. Toxicity, immune responses, changes in PSA do...
Saved in:
Published in | Clinical cancer research Vol. 15; no. 23; pp. 7375 - 7380 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.12.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: We performed a phase I clinical trial of adenovirus/prostate-specific antigen (PSA) vaccine in men with measurable metastatic
hormone-refractory disease.
Experimental Design: Men with measurable metastatic disease received one vaccine injection. Toxicity, immune responses, changes in PSA doubling
times, and patient survival were assessed. Thirty-two patients with hormone-refractory metastatic prostate cancer were treated
with a single s.c. vaccine injection at one of three dose levels, either as an aqueous solution or suspended in a Gelfoam
matrix. All patients returned for physical and clinical chemistry examinations at regular intervals up to 12 months after
injections.
Results: The vaccine was deemed safe at all doses in both administration forms. There were no serious vaccine-related adverse events;
the most prevalent were localized erythema/ecchymoses and cold/flu-like symptoms. Anti-PSA antibodies were produced by 34%
of patients and anti-PSA T-cell responses were produced by 68%. PSA doubling time was increased in 48%, whereas 55% survived
longer than predicted by the Halabi nomogram.
Conclusions: The adenovirus/PSA vaccine was proven safe with no serious vaccine-related adverse events. The majority of vaccinated patients
produced anti-PSA T-cell responses and over half survived longer than predicted by nomogram. Although the latter data are
only derived from a small number of patients in this phase I trial, they are encouraging enough to pursue further studies.
(Clin Cancer Res 2009;15(23):7375–80) |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-09-1910 |